Analysis of prescription patterns of antipsychotic agents in psychiatry

被引:0
|
作者
Montejo, A. L.
Majadas, S.
Mayoral, F.
Sanjuan, J.
Ros, S.
Olivares, J. M.
Gonzalez-Torres, M. A.
Bousono, M.
机构
[1] Hosp Univ Salamanca, Salamanca, Spain
[2] Complejo Hosp Carlos Haya, Malaga, Spain
[3] Univ Valencia, Fac Med, Valencia, Spain
[4] Hosp del Mar, Barcelona, Spain
[5] Complejo Hosp Univ, Hosp Meixoeiro, Vigo, Spain
[6] Univ Basque Country, E-48080 Bilbao, Spain
[7] Hosp Basurto, Bilbao, Spain
[8] Univ Oviedo, Oviedo, Spain
来源
ACTAS ESPANOLAS DE PSIQUIATRIA | 2006年 / 34卷 / 05期
关键词
antipsychotics; bipolar disorder; schizphrenia; psychotic disorders;
D O I
暂无
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Introduction. We describe the different diseases in which conventional and second generation antipsychotic (APS) prescriptions are made. Method. Observational, retrospective, multicenter study based on the review of 300 clinical records of public and private sites, hospital and out-patient clinics, located in Salamanca, Vigo, Bilbao, Barcelona, Valencia, Oviedo and Malaga. Results. The mean age of the population studied was 42 +/- 17 years; 56.6% were men. Atypical drugs (67%) were used basically versus classical ones (33%). Classical APS are basically prescribed in bipolar disorder with/without psychotic symptoms (20.60%), schizophrenia (18.3%) and delusional disorder (11.5%). Atypical APS are fundamentally prescribed in schizophrenia (31.5%), bipolar disorders with/without psychotic symptoms (12.5%) and other psychotic disorders (8.9%). When the psychotic disorders are considered by groups (schizophrenia, bipolar disorder with psychotic symptoms, delusional disorder and other psychotic disorders), classical APS are used in 47.4% and atypical APS in 62.5%. APS were used ((outside the indication)) (off-label) in 32.8%, including resistant depressions, serious obsessive-compulsive disorder and borderline personality disorder, with similar percentages for both conventional and atypical ones. In dementia, atypical APS were used in 5.1% versus 1.5% of the conventional ones. The most frequent reasons for prescription of classical APS were control of psychotic symptoms (33.6%), aggressiveness-agitation (31.3%), severe insomnia (16%), impulsivity (6.9%) and severe anxiety (6.1%). Atypical APS were preferably used in the control of psychotic symptoms (58.8%) and aggressiveness-agitation (25.5%). Conclusions. The use of APS basically occurs within their authorized indications (67.2%). The off-label use (32.8%) occurs both for the classical as well as atypical APS and occurs in serious diseases in which there are no alternative treatments.
引用
收藏
页码:323 / 329
页数:7
相关论文
共 50 条
  • [21] Antipsychotic prescription patterns in patients affiliated to the Social Security Health System in Colombia
    Machado-Alba, Jorge E.
    David Morales-Plaza, Cristhian
    BIOMEDICA, 2013, 33 (03): : 418 - 428
  • [22] Changes in US antidepressant and antipsychotic prescription patterns during a period of FDA actions
    Pamer, Carol A.
    Hammad, Tarek A.
    Wu, Yu-te
    Kaplan, Sigal
    Rochester, George
    Governale, Laura
    Mosholder, Andrew D.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2010, 19 (02) : 158 - 174
  • [23] Incidence, Prescription Patterns, and Determinants of Antipsychotic Use in Patients with Parkinson's Disease
    Wang, Meng-Ting
    Lian, Pei-Wen
    Yeh, Chin-Bin
    Yen, Che-Hung
    Ma, Kao-Hsing
    Chan, Agnes L. F.
    MOVEMENT DISORDERS, 2011, 26 (09) : 1663 - 1669
  • [24] Prescription patterns of antipsychotic in schizophrenic inpatients treated in the national mental hospitals in Japan
    Inagaki, A
    Fuwano, S
    Kumada, Y
    Fukuda, M
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2002, 17 : S8 - S9
  • [25] Impact of the rofecoxib withdrawal on the prescription patterns of "Simple Analgesic Agents"
    Dorais, Marc
    LeLorier, Jacques
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2008, 17 : S218 - S218
  • [26] Antipsychotic prescription amongst the elderly
    Benoit, M.
    Camus, E.
    Cnockaert, X.
    Nourashemi, F.
    Pancrazi, M. P.
    Plas, J.
    Agostino, M. I.
    Alexandra, J. -F.
    Beaufils, B.
    Cano, J. -P.
    Hazif-Thomas, C.
    Kruczek, B.
    Laurent, B.
    Michel, B. F.
    Nieoullon, A.
    Polydor, J. -P.
    Sarazin, M.
    Jeandel, C.
    CAHIERS DE L ANNEE GERONTOLOGIQUE, 2009, 1 (03): : 149 - 163
  • [27] ANTIPSYCHOTIC AGENTS
    NEW, JS
    TAKAKI, KS
    ANNUAL REPORTS IN MEDICINAL CHEMISTRY, 1989, 24 : 1 - 10
  • [28] ANTIPSYCHOTIC AGENTS
    DEPAULIS, T
    RAMSBY, S
    ANNUAL REPORTS IN MEDICINAL CHEMISTRY, 1984, 19 : 21 - 30
  • [29] ANTIPSYCHOTIC AGENTS
    VINICK, FJ
    HEYM, JH
    ANNUAL REPORTS IN MEDICINAL CHEMISTRY, 1987, 22 : 1 - 10
  • [30] ANTIPSYCHOTIC AGENTS
    NEW, JS
    TAKAKI, KS
    ANNUAL REPORTS IN MEDICINAL CHEMISTRY, 1988, 23 : 1 - 10